Phase I/II trial of valproic acid and karenitecin for metastatic malignant melanoma.
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2011
At a glance
- Drugs Cositecan (Primary) ; Valproic acid (Primary)
- Indications Malignant melanoma; Various toxicities
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 Feb 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 27 Jan 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.